he risk of coronary events
in patients with stroke or TIA. (Risk of coronary events in patients with
stroke or TIA: Two-year follow-up data from the REduction of
Atherothrombosis for Continued Health (REACH) Registry: Touze E, Rother J,
Alberts MJ, Goto S, Hill MD, Aichner F, Steg PG, Bhatt DL, Mas JL, on
behalf of the REACH Registry Investigators). Whereas the incidence rates of
MI and nonstroke vascular death are only about 1% per year, the risk rises
in patients with additional CAD to 2 to 2.5% again underlining the
increased risk of polyvascular disease.
Objectives and scope of REACH
The overall aim of the REACH Registry is to improve the assessment and
management of stroke, heart attack and associated risk factors for
atherothrombosis. It is the largest and most geographically extensive
global registry of patients at risk of atherothrombosis, having recruited
over 68,000 patients in 44 countries, covering six regions -- Latin
America, Asia, the Middle East, Australia, Europe and North America -- and
involving over 5,000 physician investigators.(4,5)
The REACH Registry includes a broad spectrum of patients with
atherothrombosis -- documenting the health status and treatment of people
at risk of atherothrombosis; monitoring how they are affected; and
measuring the burden of the disease. Patients included in the REACH
Registry either have several of the risk factors that can lead to
atherothrombosis, such as, high cholesterol, high blood pressure, smoking,
and diabetes, or have a previous history of heart attack, stroke or PAD.
Participation in the REACH Registry is strictly voluntary.
In addition, the REACH Registry is based in a real-life setting and
seeks to increase overall understanding of atherothrombotic disease across
several medical specialties (cardiology, neurology, internal medicine,
vascular medicine and office-based primary care physicians), which allows
for a more thorough assessment of the real-world burden of the diseas
'/>"/>
SOURCE REACH Registry Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)2.
Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature3.
Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services4.
D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b995.
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain8.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML9.
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials10.
Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients11.
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome